29 stories mentioning HKG:2005Updated 5d ago
Every FINWIRES story that references HKG:2005, newest first.
SSY Group's (HKG:2005) Ziprasidone Mesilate obtained registration approval to become a bulk drug for the preparations on the market from China's National Medical Products Administration.Ziprasidone Mesilate is mainly used to treat acute agitation symptoms in patients with schizophrenia, according to a Wednesday bourse filing.
SSY Group (HKG:2005) received approval from China's National Medical Products Administration for the production and registration of Letermovir Injection, according to a Thursday Hong Kong bourse filing.The 240-mg injectable drug is used to prevent cytomegalovirus infection and disease in adult recipients who are CMV-seropositive after allogeneic hematopoietic stem cell transplantation.
SSY Group's (HKG:2005) Diltiazem Hydrochloride Tablets' (30mg) passing of the quality and efficacy consistency evaluation was approved by China's National Medical Products Administration.The drug is mainly used to treat angina pectoris and mild to moderate essential hypertension, according to a Wednesday Hong Kong bourse filing.
SSY Group (HKG:2005) said the trustee of its share scheme bought 1 million shares from the open market on Sept. 1, according to a same-day Hong Kong bourse filing.The shares were purchased for approximately HK$2.73 million, excluding fees, using the company's internal resources.
SSY Group (HKG:2005) obtained drug production and registration approval for Ozagrel Sodium Injection from China's National Medical Products Administration.The move came as the drug was regarded as having passed the regulator's consistency evaluation, according to a Tuesday Hong Kong bourse filing.The product is mainly used to treat acute thrombotic cerebral infarction and motor dysfunction associated with cerebral infarction.
SSY Group (HKG:2005) obtained approval for the production and registration of Vitamin K1 Injection from China's National Medical Products Administration.The product is regarded as having passed China's consistency evaluation, according to a Thursday Hong Kong bourse filing.The injection is mainly used to treat and prevent bleeding associated with vitamin K deficiency.Shares of the pharmaceutical company rose 4% in recent trade.
SSY Group (HKG:2005) obtained drug production and registration approvals for four products from China's National Medical Products Administration.The move came as the products passed the regulator's consistency evaluation, according to a Thursday Hong Kong bourse filing.The drug candidates include Potassium Chloride Injection (Ⅱ) for the treatment of hypokalemia and Metoclopramide Tablets (5mg) for the symptomatic treatment of nausea and vomiting caused by various diseases.The remaining two approvals are for Sodium Hyaluronate Eye Drops 0.1% for dry eye and 0.3% for corneal and conjunctival epithelial damage.
SSY Group's (HKG:2005) 13 products covering 16 specifications were selected in the 12th round of China's National Centralised Medicines Procurement program.The selected products include Blonanserin Tablets, Vitamin B6 Injection, Acipimox Capsules, Doxazosin Mesylate Extended Release Tablets, Bumetanide Injection, Pentoxifylline Sustained-release Tablets, Deferasirox Dispersible Tablets and Calcium Chloride Injection, among others, according to a Hong Kong bourse filing.
SSY Group (HKG:2005) obtained drug production and registration approvals for four products from China's National Medical Products Administration as they pass the regulator's consistency evaluation.The approvals are for Hemofiltration Replacement Fluid of Sodium Citrate used as replacement fluid in continuous renal replacement therapy and Benidipine Hydrochloride Tablets for the treatment of primary hypertension and angina pectoris.The other two products comprise Polyvinyl Alcohol Eye Drops as a lubricant for dry eyes and a Fat Emulsion, Amino Acids and Glucose Injection for adult patients.
SSY Group (HKG:2005) said its Gadobutrol bulk drug has received marketing registration approval from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The approval allows the active pharmaceutical ingredient to be used in marketed Gadobutrol preparations.Gadobutrol is a magnetic resonance imaging contrast agent used in adults and children for contrast-enhanced MRI and magnetic resonance angiography examinations, the filing said.
SSY Group (HKG:2005) said its Choline Fenofibrate Sustained-release Capsules have received drug registration approval from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.The product is approved as a Class 4 chemical drug and has passed the consistency evaluation.Choline Fenofibrate Sustained-release Capsules are used to lower triglyceride levels in adults with severe hypertriglyceridemia and to treat patients with primary hypercholesterolemia or mixed dyslipidemia, the filing said.
SSY Group (HKG:2005) said its Baloxavir Marboxil has received registration approval from China's National Medical Products Administration as a bulk drug for marketed preparations, according to a Hong Kong bourse filing Monday.Baloxavir Marboxil is used to treat influenza A and influenza B, the filing said.
SSY Group (HKG:2005) obtained production and registration approval for the Propylthiouracil Tablets and Calcium Gluconate and Sodium Chloride Injection from China's National Medical Products Administration.The move came as the drugs were regarded as passing the regulator's consistency evaluation, according to a Friday Hong Kong bourse filing.The Propylthiouracil Tablets are mainly used for various types of hyperthyroidism intolerant to methimazole.The Calcium Gluconate and Sodium Chloride Injection is used to treat acute hypocalcemia, magnesium poisoning, and fluoride poisoning, and has formed a calcium preparation product series along with the company's other products.
SSY Group (HKG:2005) said 32 of its products, comprising 37 specifications, were newly included in the 2026 edition of China's National Essential Medicines List.This brings the total number of the group's products on the list to 95, covering 141 specifications, according to a Friday Hong Kong bourse filing. The updated list will take effect on Sept. 1.The pharmaceutical company said the inclusion is expected to support its business growth and development.Shares of the pharmaceutical company rose 2% in recent trade.
SSY Group (HKG:2005) obtained production and registration approval for Methocarbamol Tablets and registration approval for Phloroglucinol Dihydrate from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The approval for Methocarbamol Tablets came as the drug passed the regulator's consistency evaluation.Methocarbamol Tablets are muscle relaxants mainly used to treat joint and muscle sprains, lumbar muscle strain, and sciatica.Phloroglucinol Dihydrate is used to treat acute spasmodic pain associated with digestive, biliary, urinary, and gynecological conditions.Shares of the firm were up nearly 5% in late morning trade on Thursday.
SSY Group (HKG:2005) obtained production and registration approvals for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The approval came as the drugs passed the regulator's consistency evaluation.Safinamide Mesylate Tablets are mainly used in adult patients with primary Parkinson's disease and symptom fluctuation, in combination with other drugs for Parkinson's.The Procaterol Hydrochloride Inhalation Solution is used to provide relief for airflow limitation symptoms in bronchial asthma, chronic bronchitis, and emphysema.
SSY Group (HKG:2005) obtained production and registration approval for Cefpodoxime Proxetil for Suspension from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The move came after the drug was regarded as passing the regulator's consistency evaluation, the pharmaceutical company said.The drug is used to treat infections caused by susceptible bacteria, including upper and lower respiratory tract, uncomplicated urinary tract, and uncomplicated skin and soft tissue infections.The drug also treats acute uncomplicated gonococcal urethritis and cervicitis, as well as perianal inflammation caused by Neisseria gonorrhoea.
SSY Group (HKG:2005) said its Shijiazhuang No. 4 Pharmaceutical unit is negotiating an exclusive license for peritoneal dialysis treatment OPT101, according to a Monday filing with the Hong Kong bourse.The firm signed a letter of intent with the drug's developer, Opterion Health, for a possible license covering China that would expire in 2038. The SSY Group unit will also receive priority over licenses covering Hong Kong, Taiwan, and Russia.A formal agreement is expected in the third quarter of 2026, SSY Group said.Shares of SSY gained over 1% in recent trade.
SSY Group (HKG:2005) said it entered exclusive negotiations with Hebei Longhai Pharmaceutical over four biosimilar drugs, according to a Friday filing with the Hong Kong bourse.Under the letter of intent, the firm may license biosimilar versions of ustekinumab, dupilumab, aflibercept, and evolocumab from Longhai Pharmaceutical, which will be responsible for completing research and technical know-how on the medicines.The company will be required to make a down payment and milestone payments to Longhai Pharmaceutical if the deal materializes.The exclusivity period for negotiations will last 90 days, the firm said.
SSY Group (HKG:2005) obtained registration approval for Safinamide Mesylate to become a bulk drug for the preparations on the market from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug is mainly used for the treatment of Parkinson's disease in combination with other Parkinson's drugs such as levodopa, the filing said.
Showing 1-20 of 29
